-
Royalty Products
On the forefront of technology, we continue to challenge ourselves to create the most value for patients and physicians through the development and acquisition of advanced therapies.
Since our inception in 1981, we at Enzon are committed to transforming patient care. On the forefront of technology, we continue to challenge ourselves to create the most value for patients and physicians through the development and acquisition of advanced therapies. So far, Enzon has four products on which are on the market through the dedicated work of our employees and strategic acquisitions by our senior leaders.
Enzon is committed to providing access to life saving therapies for patients with life threatening diseases. We currently market ONCASPAR®, DEPOCYT® , ADAGEN®, and ABELCET®. Our staff of sales and marketing professionals is committed to making a positive impact on patients with serious and chronic illnesses.
Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.81 | ||
| Change(%) |  | 0.00 | |
| Volume | 278301 | ||
| 1:58 PM - Mar 09, 2010 | |||
News
-
09-10-2009
Enzon to Present at NewsMakers...
Enzon to Present at NewsMakers in the Biotech Industry Conference
-
07-27-2009
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
-
07-27-2009
Enzon to Present at BMO Focus...
Enzon to Present at BMO Focus on Healthcare Conference
-
07-23-2009
Enzon Enhances Governance with...
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
-
02-13-2009
Enzon to Release Fourth Quarte...
Enzon to Release Fourth Quarter 2008 Earnings on Thursday, February 19, 2009; Conference Call and Webcast to Follow
-
05-28-2008
Jack Geltosky, Ph.D. Joins Enz...
Jack Geltosky, Ph.D. Joins Enzon's Board of Directors
-
12-31-1969
Enzon Pharmaceuticals to Add N...
Enzon Pharmaceuticals to Add New Independent Director to Board
-
02-14-2008
Enzon Reports Significant Prog...
Enzon Reports Significant Progress on the Reduction of Its Debt
-
04-23-2009
Enzon Continues to Improve its...
Enzon Continues to Improve its Capital Structure
-- Company repurchased $17.5 million of its outstanding debt at a discount to par-- -
08-06-2008
Enzon Reports Solid Second Qua...
Enzon Reports Solid Second Quarter 2008 Results
-- Product revenues increase 17% -- -
05-20-2008
Enzon Announces Clinical Data...
Enzon Announces Clinical Data From PEG-SN38 and rhMBL Studies at ASCO -- Company will host reception --
-
03-17-2008
Enzon's PEG-SN38 Featured in C...
Enzon's PEG-SN38 Featured in Clinical Cancer Research